Proton Radiation for Lymphoma Involving Mediastinum
NCT01751412 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2017-11-24
Summary
This research study is a Pilot Study. Pilot studies are conducted to see if it is practical to do this type of research on a larger scale in the future. The pilot part of this study is to assess the possibility of using proton radiation to treat lymphomas. Proton radiation is used for many other types of malignancies, but its use for the treatment of lymphoma has been limited. The treatment is still being studied as research doctors are trying to find out more about its use in the treatment of different types of lymphoma. Proton beam radiation therapy is an FDA approved radiation delivery system.
Patients are being asked to participate in this research study if they have lymphoma in the center of their chest, near their heart. Conventional radiation therapy with photons is used as standard treatment for many patients with lymphoma. In this research study investigators are looking at another type of radiation called proton radiation, which is known to spare surrounding tissue and organs from radiation. Proton radiation delivers radiation to the area requiring radiation but delivers no dose beyond the region requiring treatment. This may reduce side effects that patients would normally experience with conventional radiation therapy or other means of delivering proton radiation therapy.
In this research study, investigators are evaluating the effectiveness of using proton radiation delivered to reduce side effects associated with radiation treatment.
Conditions
Interventions
- RADIATION
-
Proton Radiation
Sponsors & Collaborators
-
Massachusetts General Hospital
lead OTHER
Principal Investigators
-
Thomas DeLaney, MD · Massachusetts General Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-02-28
- Primary Completion
- 2016-10-31
- Completion
- 2017-02-28
Countries
- United States
Study Locations
More Related Trials
-
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00278408 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
NCT00001237 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
NCT01144754 ·Status: TERMINATED
-
Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma
NCT03742804 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
NCT01729104 ·Status: TERMINATED ·Phase: PHASE1
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
NCT02061449 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
NCT00141700 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
NCT00248534 ·Status: TERMINATED ·Phase: PHASE2
-
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
NCT01119794 ·Status: TERMINATED ·Phase: PHASE2
-
This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas
NCT01279772 ·Status: TERMINATED
-
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
NCT01806337 ·Status: COMPLETED ·Phase: PHASE2
-
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT06675123 ·Status: RECRUITING ·Phase: PHASE1
-
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
NCT03311126 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
NCT00134082 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00003605 ·Status: WITHDRAWN ·Phase: PHASE2
-
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
NCT00023166 ·Status: TERMINATED ·Phase: PHASE1
-
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00008021 ·Status: UNKNOWN ·Phase: PHASE1
-
Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors
NCT00001301 ·Status: COMPLETED
-
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01415752 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT00594815 ·Status: COMPLETED ·Phase: NA
-
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
NCT06813573 ·Status: RECRUITING ·Phase: NA
-
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
NCT02530125 ·Status: TERMINATED ·Phase: PHASE2
-
Radiotherapy in Primary Mediastinal Lymphoma
NCT01230008 ·Status: COMPLETED